Dolca Thomas
Overview
Explore the profile of Dolca Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
848
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuter D, Efraim M, Mayer J, Trneny M, McDonald V, Bird R, et al.
N Engl J Med
. 2022 Apr;
386(15):1421-1431.
PMID: 35417637
Background: Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fcγ...
2.
Ucpinar S, Darpo B, Neale A, Nunn P, Shu J, Chu K, et al.
Clin Transl Sci
. 2022 Mar;
15(6):1507-1518.
PMID: 35301810
This study aimed to define the clinically relevant supratherapeutic dose of rilzabrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, and evaluate potential effects of therapeutic and supratherapeutic exposures on cardiac...
3.
Cohen S, Emery P, Greenwald M, Yin D, Becker J, Melia L, et al.
Br J Clin Pharmacol
. 2016 Feb;
82(1):129-38.
PMID: 26909489
Aims: Pharmacokinetic (PK) similarity was assessed among PF-05280586 (a proposed biosimilar) vs. rituximab sourced from the European Union (rituximab-EU) and the United States (rituximab-US). Pharmacodynamics (PD), overall safety and immunogenicity...
4.
Li E, Subramanian J, Anderson S, Thomas D, McKinley J, Jacobs I
Drug Des Devel Ther
. 2015 Jul;
9:3247-55.
PMID: 26150698
Acute and chronic shortages of various pharmaceuticals and particularly of sterile injectable products are being reported on a global scale, prompting evaluation of more effective strategies to manage current shortages...
5.
Socinski M, Curigliano G, Jacobs I, Gumbiner B, Macdonald J, Thomas D
MAbs
. 2015 Jan;
7(2):286-93.
PMID: 25621390
Despite availability of biologic therapies, limited patient access to many of the most-effective cancer treatments affects overall health outcomes. To address this issue, many governments have enacted legislation for the...
6.
Grinyo J, Alberu J, Contieri F, Manfro R, Mondragon G, Nainan G, et al.
Transpl Int
. 2012 Jul;
25(10):1059-64.
PMID: 22816557
Kidney transplant recipients who switched from a calcineurin inhibitor (CNI) to belatacept demonstrated higher calculated glomerular filtration rates (cGFRs) at 1 year in a Phase II study. This report addresses...
7.
Kawabata T, Weaver J, Thomas D, Rowe M, Wang F, Kamperschroer C, et al.
J Immunotoxicol
. 2011 Dec;
9(1):121-7.
PMID: 22136193
Epstein-Barr virus (EBV)-associated lymphomas are a known risk for immunosuppressed individuals. Non-clinical methods to determine the potential of new immunomodulatory compounds to produce EBV-associated lymphomas (hazard identification) have not been...
8.
Kasiske B, Kukla A, Thomas D, Wood Ives J, Snyder J, Qiu Y, et al.
Am J Kidney Dis
. 2011 Sep;
58(6):971-80.
PMID: 21930332
Background: Posttransplant lymphoproliferative disorder (PTLD) is a major complication of kidney transplant. Study Design: Retrospective cohort study comparing PTLD incidence rates using US Medicare claims and Organ Procurement and Transplantation...
9.
Rostaing L, Neumayer H, Reyes-Acevedo R, Bresnahan B, Florman S, Vitko S, et al.
Clin J Am Soc Nephrol
. 2011 Sep;
6(11):2696-704.
PMID: 21921152
Background And Objectives: Renal transplant recipients with pre-existing diabetes (PD) have reduced graft survival and increased risk of mortality and ischemic heart disease compared with nondiabetic transplant recipients. To assess...
10.
Grinyo J, Charpentier B, Pestana J, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, et al.
Transplantation
. 2010 Nov;
90(12):1521-7.
PMID: 21088650
Background: Belatacept is associated with better renal function and an improved cardiovascular/metabolic risk profile versus cyclosporine in kidney transplant recipients. The current analysis examined pooled safety data for belatacept versus...